HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

Find the next decision worth funding

Explore Opportunities

Most actionable first. Assess the next decision, not the size of the database.

Refine the decision · 12 filters (subscription required)
Reset filters

1 matching trial–asset observations. These are not unique or cleared acquisitions. 0 have all four gates supported in this view; entered assessments still require review.

How “most actionable” works

Explicit ordinal order: all four gates PASS → concerns needing review → unresolved leads → fatal failures. Names and IDs break ties. UNKNOWN never counts as a pass. This is not an efficacy score or valuation. Private assumptions affect only your own results.

WATCH · SUSPENDED

celecoxib

Non-Small Cell Lung Cancer

Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

SOURCE FACT No stopping reason reported; not proof of abandonment

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity
Source, stopping context and uncertainty

No stopping reason reported; not proof of abandonment

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update UNKNOWN. Registry source